Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial.

Abstract:

BACKGROUND:The well-described morning peak in the onset of acute coronary syndromes has been partly attributed to increased platelet activity upon arising. It has been suggested that stent thrombosis (ST) exhibits a similar pattern. We assessed whether a diurnal variation in ST occurs, and whether more robust antiplatelet therapy with prasugrel (vs clopidogrel) can attenuate a morning excess. METHODS AND MATERIALS:Patients from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38 trial (N = 13 608) with adjudicated ST classified per the Academic Research Consortium definitions of definite (N = 135) and probable (N = 27) were grouped into prespecified 8-hour intervals by time of onset: early (6 am-2 pm), late-day (2 pm-10 pm), and overnight (10 pm-6 am). We compared the rates per 1000 patients of ST across time intervals and stratified by treatment and stent type. RESULTS:A diurnal variation in definite/probable ST was observed with rates of 6.5, 3.7, and 2.1 for early, late-day, and overnight intervals, respectively (P < .001), per 1000 patients treated. A sensitivity analysis excluding periprocedural acute-ST (<24 hours after index percutaneous coronary intervention [PCI]) resulted in similar findings (5.2, 2.5, and 1.8 per 1000, P < .001). The circadian variation in ST was observed in patients on clopidogrel (9.7, 4.8, and 3.1 per 1000, P < .001) with the highest rate of ST early in the day. Patients on prasugrel also demonstrated a circadian variation with particularly low rates of overnight ST (3.4, 3.0, and 1.1 per 1000, P = .020). CONCLUSIONS:In TRITON-TIMI 38 trial, the timing of ST exhibited a significant diurnal variation similar to that seen with onset of other acute coronary syndromes. ST occurred less frequently among patients randomized to prasugrel compared to clopidogrel with the greatest absolute reduction (6.2 per 1000 patients) in events earlier in the day when platelet activity is known to be highest.

authors

Mogabgab O,Wiviott SD,Cannon CP,Sloan S,Sabatine MS,Antman EM,Braunwald E,Giugliano RP

doi

10.1177/1074248413497534

subject

Has Abstract

pub_date

2013-11-01 00:00:00

pages

555-9

issue

6

eissn

1074-2484

issn

1940-4034

pii

1074248413497534

journal_volume

18

pub_type

杂志文章,随机对照试验
  • Effect of Digoxin on Ventricular Remodeling and Responsiveness of beta-Adrenoceptors in Chronic Volume Overload.

    abstract::BACKGROUND: Digoxin improves baroreflex function and reduces neurohumoral activation in severe heart failure, but it is uncertain how digoxin affects ventricular remodeling and progression to left ventricular dysfunction. In addition, the effect of digoxin in in vitro beta-adrenoceptor density and function, and contra...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424849800300403

    authors: Sullebarger JT,D'Ambra PM,Clark LC,Thanikarry L,Fontanet HL

    更新日期:1998-10-01 00:00:00

  • Sarcoplasmic reticulum adenosine triphosphatase overexpression in the L-type Ca2+ channel mouse results in cardiomyopathy and Ca2+ -induced arrhythmogenesis.

    abstract:BACKGROUND:Overexpression of the L-type voltage-dependent calcium channel alpha(1C)-subunit (L-VDCC OE) in transgenic mice results in adaptive hypertrophy followed by a maladaptive phase associated with a decrease in sarcoplasmic reticulum adenosine triphosphatase (SERCA)2a expression at 8 to 10 months of age. Overexpr...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424840501000404

    authors: Rubio M,Bodi I,Fuller-Bicer GA,Hahn HS,Periasamy M,Schwartz A

    更新日期:2005-12-01 00:00:00

  • Nonplatelet effects of aspirin during acute coronary occlusion: electrophysiologic and cation alterations in ischemic myocardium.

    abstract:BACKGROUND:Mortality after acute myocardial ischemia has been reduced by aspirin (ASA) but mechanisms other than the antiplatelet effect have not been established. This article evaluates an antiarrhythmic action during sympathetic stimulation in the intact anesthetized dog with and without ischemia. METHODS AND RESULT...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1053/XV.2000.5492

    authors: Shehadeh AA,Arena J,Moschos CB,Regan TJ

    更新日期:2000-04-01 00:00:00

  • Molecular Delivery System for Antisense Oligonucleotides: Enhanced Effectiveness of Antisense Oligonucleotides by HVJ-liposome Mediated Transfer.

    abstract::BACKGROUND: The effectiveness of antisense oligodeoxynucleotides for in vitro and in vivo studies is limited by a low efficiency of cellular uptake and instability due to degradation by nucleases. To overcome some of these problems, we recently developed a transfer method that utilizes inactivated Sendai virus (hemagg...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424849700200308

    authors: Morishita R,Gibbons GH,Horiuchi M,Nakajima M,Ellison KE,Lee W,Kaneda Y,Ogihara T,Dzau VJ

    更新日期:1997-07-01 00:00:00

  • Remote Ischemic Conditioning in Cardiovascular Surgery.

    abstract::The existing clinical studies on remote ischemic preconditioning in patients undergoing cardiovascular surgery are critically reviewed, with a focus on infarct size reduction and clinical outcome as end points. Confounders, notably the use of propofol anesthesia are identified. The need for better designed trials with...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248416687874

    authors: Heusch G

    更新日期:2017-07-01 00:00:00

  • Omapatrilat induces profound renal vasodilation but does not affect coronary hemodynamics.

    abstract:BACKGROUND:Omapatrilat has potent enzymatic inhibitory effects on the angiotensin-converting enzyme and neutral endopeptidase. The prolonged effects of this inhibition on systemic and regional hemodynamics, cardiovascular mass, and hydroxyproline concentration in spontaneously hypertensive rats were studied. The contri...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424840300800210

    authors: Varagic J,Susic D,Slama M,Frohlich ED

    更新日期:2003-06-01 00:00:00

  • Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension.

    abstract::Pulmonary arterial hypertension (PAH) is a progressive disease, which can be potentially fatal. The management of a complex disease like PAH requires a multidisciplinary approach from a team consisting of physicians, nurses, social workers, and pharmacists. Adherence to PAH-specific therapy is one of the key factors i...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248419877409

    authors: Narechania S,Torbic H,Tonelli AR

    更新日期:2020-03-01 00:00:00

  • Roles of cyclooxygenase 2 in sevoflurane- and olprinone-induced early phase of preconditioning and postconditioning against myocardial infarction in rat hearts.

    abstract:PURPOSE:It is known that selective cyclooxygenase 2(COX-2) inhibitors increase mortality in patients with previous myocardial infarction, and it has been suggested that COX-2 plays an important role in cardioprotection against ischemia. The current study was carried out to determine whether COX-2 is involved in the mec...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248410380208

    authors: Tosaka S,Tosaka R,Matsumoto S,Maekawa T,Cho S,Sumikawa K

    更新日期:2011-03-01 00:00:00

  • Ischemic Conditioning in Kidney Transplantation.

    abstract::Ischemia-reperfusion injury is a composite of the injury sustained during a period of reduced or absent blood flow to a tissue or organ and the additional insult sustained on reperfusion, which limits the amount of tissue that can be salvaged. Ischemia-reperfusion injury is the predominant insult during kidney transpl...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248417702893

    authors: Veighey K,MacAllister R

    更新日期:2017-07-01 00:00:00

  • Antiplatelet Therapy Considerations in Ischemic Cardiogenic Shock: Implications of Metabolic Bioactivation.

    abstract::Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist remains a mainstay in the prevention of ischemic events following coronary stent placement. Significant controversy exists regarding the optimal management of high platelet reactivity despite antiplatelet therapy; however this finding has been cons...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248415571456

    authors: Weeks PA,Sieg A,Paruthi C,Rajapreyar I

    更新日期:2015-07-01 00:00:00

  • Right atrial and ventricular thrombus infiltrated with osteoblastic osteosarcoma.

    abstract::The presenting signs of osteogenic osteosarcoma are commonly pain, local swelling, local warmth, pathologic fracture, and metastatic disease. Deep venous metastasis of osteoblastic osteosarcoma is most often a postmortem diagnosis. This paper describes the case of a previously healthy 18-year-old woman who presented w...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424840300800408

    authors: Shah AP,Parmar S,O'Regan R

    更新日期:2003-12-01 00:00:00

  • Cardiovascular risk of selective cyclooxygenase-2 inhibitors.

    abstract::Recently, cyclooxygenase-2 (COX-2) inhibitors (coxibs), a class of drugs intended to be painkillers, have created unprecedented controversy because of their cardiovascular risk profile. The controversy has affected the patients, health-care providers, the Food and Drug Administration, and the manufacturers of these ag...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/107424840501000203

    authors: Schrör K,Mehta P,Mehta JL

    更新日期:2005-06-01 00:00:00

  • Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure.

    abstract:BACKGROUND:epidemiologic studies indicate that elevated heart rate (HR) is an independent risk factor for mortality and morbidity in patients (pts) with chronic heart failure (CHF). Clinical trials with β-blockers suggest that HR reduction is an important mechanism of their benefit in pts with stable CHF. Pharmacologic...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/1074248410370326

    authors: Sarullo FM,Fazio G,Puccio D,Fasullo S,Paterna S,Novo S,Di Pasquale P

    更新日期:2010-12-01 00:00:00

  • Postconditioning markedly attenuates ventricular arrhythmias after ischemia-reperfusion.

    abstract:BACKGROUND:Brief periods of reocclusion (postconditioning) during early reperfusion reduce myocardial infarct size. Whether postconditioning has an effect on lethal ventricular arrhythmias independent of infarction in an in-vivo regional ischemia model is unknown. The purpose of this study was to determine if postcondi...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424840601100105

    authors: Kloner RA,Dow J,Bhandari A

    更新日期:2006-03-01 00:00:00

  • Novel oral anticoagulants in cardiovascular disease.

    abstract::Nonvalvular atrial fibrillation (AF) confers an increased risk of thromboembolism, with a 5-fold higher risk of ischemic stroke. Oral anticoagulation (OAC) has shown to be highly effective in preventing stroke and mortality compared to placebo and is also used in patients without AF for both treatment and prophylaxis ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248413501392

    authors: Gallego P,Roldán V,Lip GY

    更新日期:2014-01-01 00:00:00

  • Comparing Diuresis Patterns in Hospitalized Patients With Heart Failure With Reduced Versus Preserved Ejection Fraction: A Retrospective Analysis.

    abstract:BACKGROUND:Congestion predominates in exacerbations of heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF), but evidence suggests that excess volume may be distributed differently in these 2 subgroups. METHODS AND RESULTS:In this retrospective study, diuretic efficiency (DE, or ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248420960930

    authors: Broscious R,Kukin A,Noel ZR,Devabhakthuni S,Seung H,Ramani GV,Reed BN

    更新日期:2021-03-01 00:00:00

  • Different Effects of Volatile and Nonvolatile Anesthetic Agents on Long-Term Survival in an Experimental Model of Hemorrhagic Shock.

    abstract:BACKGROUND:We investigated whether the cardioprotective, volatile gas anesthetic agent, isoflurane, could improve survival and organ function from hemorrhagic shock in an experimental rat model, compared to standard nonvolatile anesthetic agent ketamine/xylazine. METHODS:Sprague Dawley rats (both genders) were randomi...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248420919221

    authors: Dai W,Shi J,Carreno J,Kloner RA

    更新日期:2020-07-01 00:00:00

  • Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.

    abstract::Levosimendan increases the sensitivity of the cardiac fibrils to calcium, favorably affects hemodynamics in patients with heart failure. It is a positive inotrope and a peripheral vasodilator. The elimination half-life of the compound is about 1 hour. The drug decreases pulmonary capillary wedge pressure, increases ca...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248408324550

    authors: Kota B,Prasad AS,Economides C,Singh BN

    更新日期:2008-12-01 00:00:00

  • Increasing doses of simvastatin versus combined ezetimibe/simvastatin: effect on circulating endothelial progenitor cells.

    abstract:BACKGROUND:Patients with coronary artery disease (CAD) should be treated with statins to attain very low cholesterol levels, in order to reduce cardiovascular adverse events. More than 70% of these patients do not reach the appropriate cholesterol goal despite moderate statin doses. However, it is not known whether the...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/1074248413489771

    authors: Pesaro AE,Serrano CV Jr,Katz M,Marti L,Fernandes JL,Parra PR,Campos AH

    更新日期:2013-09-01 00:00:00

  • Electrical Integration of Human Embryonic Stem Cell-Derived Cardiomyocytes in a Guinea Pig Chronic Infarct Model.

    abstract:BACKGROUND:Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) were recently shown to be capable of electromechanical integration following direct injection into intact or recently injured guinea pig hearts, and hESC-CM transplantation in recently injured hearts correlated with improvements in contractile funct...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248413520344

    authors: Shiba Y,Filice D,Fernandes S,Minami E,Dupras SK,Biber BV,Trinh P,Hirota Y,Gold JD,Viswanathan M,Laflamme MA

    更新日期:2014-07-01 00:00:00

  • State of the science of cardioprotection: Challenges and opportunities--proceedings of the 2010 NHLBI Workshop on Cardioprotection.

    abstract::The National Heart, Lung, and Blood Institute convened a Workshop on September 20-21, 2010, "New Horizons in Cardioprotection," to identify future research directions for cardioprotection against ischemia and reperfusion injury. Since the early 1970s, there has been evidence that the size of a myocardial infarction co...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type:

    doi:10.1177/1074248411402501

    authors: Kloner RA,Schwartz Longacre L

    更新日期:2011-09-01 00:00:00

  • Exploring the Quality of Anticoagulant Prescribed for Patients With Atrial Fibrillation at the St John of God Hawkesbury District Health Centre, New South Wales, Australia.

    abstract:BACKGROUND:Limited data are available on the clinical management of atrial fibrillation (AF) and its outcomes from an Australian perspective. OBJECTIVE:To describe the appropriateness of antithrombotic prescribing for patients who presented with a diagnosis of AF to the Hawkesbury St John of God Hospital, New South Wa...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248418786264

    authors: Wertheimer G,Bereznicki LR

    更新日期:2019-01-01 00:00:00

  • Regression of Atherosclerotic Plaques of Cholesterol-Fed Rabbits by Combined Chemotherapy With Paclitaxel and Methotrexate Carried in Lipid Core Nanoparticles.

    abstract::In previous studies, it was demonstrated that lipid core nanoparticles (LDE) resemble the low-density lipoprotein structure and carrying the antiproliferative agent paclitaxel (PTX) strongly reduced atherosclerosis lesions induced in rabbits by cholesterol feeding. Currently, the aim was to verify whether combining LD...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248418778836

    authors: Gomes FLT,Maranhão RC,Tavares ER,Carvalho PO,Higuchi ML,Mattos FR,Pitta FG,Hatab SA,Kalil-Filho R,Serrano CV Jr

    更新日期:2018-11-01 00:00:00

  • Effect of potassium-channel opener therapy on reperfused infarction in hypertrophied hearts: demonstration of preconditioning by using functional and contrast-enhanced magnetic resonance imaging.

    abstract::Effects of therapy with the potassium-channel opener and vasodilator nicorandil were studied in reperfused infarction of hypertrophied hearts by using magnetic resonance imaging (MRI), hemodynamic measurements, and histochemical staining. Aortic banding was performed on 22 Sprague-Dawley rats to induce left ventricula...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424840400900307

    authors: Schalla S,Higgins CB,Chujo M,Saeed M

    更新日期:2004-09-01 00:00:00

  • Astaxanthin reduces oxidative stress, but not aortic damage in atherosclerotic rabbits.

    abstract::We evaluated whether carotenoid astaxanthin (ASX) could prevent oxidative and atherosclerotic damage in rabbits. Rabbits received regular chow (control) or an atherogenic diet (1% cholesterol) alone or supplemented with 50, 100, and 500 mg% ASX for 60 days (n = 5-9 per group). The atherogenic diet increased the serum ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248409350136

    authors: Augusti PR,Conterato GM,Somacal S,Sobieski R,Quatrin A,Maurer L,Rocha MP,Denardin IT,Emanuelli T

    更新日期:2009-12-01 00:00:00

  • The cycloxygenase 2 (COX-2) story: it's time to explain, not inflame.

    abstract::Despite initial promising reports that anti-inflammatory properties of cycloxygenase-2 (COX-2) inhibitors may confer anti-atherosclerosis effects and stabilize the atherosclerotic plaque, subsequent data from long-term clinical trials have shown that selective COX-2 inhibitors are associated with increased risk of car...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248407301172

    authors: Salinas G,Rangasetty UC,Uretsky BF,Birnbaum Y

    更新日期:2007-06-01 00:00:00

  • Electrophysiologic effects of a novel selective adenosine A1 agonist (CVT-510) on atrioventricular nodal conduction in humans.

    abstract:BACKGROUND:CVT-510, N-(3(R)-tetrahydrofuranyl)-6-aminopurine riboside, is a selective A(1)-adenosine receptor agonist with potential potent antiarrhythmic effects in tachycardias involving the atrioventricular (AV) node. This study, the first in humans, was designed to determine the effects of CVT-510 on AV nodal condu...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1177/107424840100600304

    authors: Lerman BB,Ellenbogen KA,Kadish A,Platia E,Stein KM,Markowitz SM,Mittal S,Slotwiner DJ,Scheiner M,Iwai S,Belardinelli L,Jerling M,Shreeniwas R,Wolff AA

    更新日期:2001-07-01 00:00:00

  • AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.

    abstract:BACKGROUND:Hypertension is a major cause of death and morbidity worldwide and is increasing in prevalence. The Renin-angiotensin system (RAS) is the most common mechanism involved in the pathophysiology of hypertension. Understanding the mechanism of the pathophysiologic processes will help direct potential therapeutic...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248419838503

    authors: Zhao Y,Ma R,Yu X,Li N,Zhao X,Yu J

    更新日期:2019-09-01 00:00:00

  • Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies.

    abstract::The primary effect of ischemia is reduced aerobic adenosine triphosphate (ATP) formation in mitochondria. This triggers accelerated glycolysis and reduced cell pH, Ca(2+) accumulation, K(+) efflux, adenosine formation, and the clinical signs of ischemia: chest pain and a shift in the ST segment. Traditional therapies ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/107424840400900104

    authors: Stanley WC

    更新日期:2004-09-01 00:00:00

  • A Quarter of a Century Later: What is Dofetilide's Clinical Role Today?

    abstract::Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials showed neutral mortality in post-myocardial infarction patients and th...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248418784288

    authors: Wolbrette DL,Hussain S,Maraj I,Naccarelli GV

    更新日期:2019-01-01 00:00:00